— Know what they know.
Not Investment Advice
Also trades as: 0M40.L (LSE) · $vol 0M

ZYNE NASDAQ

Zynerba Pharmaceuticals, Inc.
1W: +1.6% 1M: -3.7% 3M: +271.4% 1Y: +90.9% 3Y: -64.0% 5Y: -81.4%
$1.30
Last traded 2023-10-13 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $70.1M mcap · 35M float · 3.24% daily turnover

Balance Sheet Trends

Total Assets
$56M -31.6% ▼
5Y CAGR: -4.3%
Total Liabilities
$9M -9.4% ▼
5Y CAGR: +2.8%
Shareholders Equity
$46M -34.8% ▼
5Y CAGR: -5.4%
Cash & Investments
$51M -25.3% ▼
5Y CAGR: -4.1%
Total Debt
$334K -40.6% ▼
Net Debt
-$50M +25.2% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2018FY2019FY2020FY2021FY2022
— Assets —
Cash$60M$70M$59M$68M$51M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$60M$70M$59M$68M$51M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$7M$17M$14M$12M$4M
Total Current Assets$67M$87M$73M$80M$55M
Property, Plant & Equip.$372K$709K$691K$952K$746K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$372K$709K$691K$952K$746K
Total Assets$67M$88M$74M$81M$56M
— Liabilities —
Accounts Payable$4M$5M$3M$2M$2M
Short-Term Debt$0$244K$110K$209K$215K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$5M$7M$11M$8M$7M
Total Current Liabilities$10M$12M$14M$10M$9M
Long-Term Debt$0$110K$0$354K$120K
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$0$110K$0$354K$120K
Total Liabilities$10M$12M$14M$10M$9M
— Equity —
Common Stock$18K$23K$30K$41K$48K
Retained Earnings-$118M-$151M-$202M-$239M-$275M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$58M$76M$60M$71M$46M
Total Liabilities & Equity$67M$88M$74M$81M$56M
— Key Metrics —
Total Debt$0$353K$110K$563K$334K
Net Debt-$60M-$70M-$59M-$67M-$50M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms